.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,939,530

« Back to Dashboard

Details for Patent: 7,939,530

Title:Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabine
Abstract: Lymphoma is treated using therapeutic combinations of PDX and gemcitabine by administering to a patient suffering from lymphoma a therapeutically effective amount of PDX in combination with a therapeutically effective amount of gemcitabine. The two agents can be administered together or in either order, although administration of PDX followed by gemcitabine is preferred. As in the case of MTX and Ara-C, synergism is observed, but the extent of the synergism is greater. Further, test results indicate that mechanism of action for combinations of PDX and Gem is different than for MTX and Ara-C, with more emphasis on induction of apoptosis.
Inventor(s): O'Connor; Owen A (Scarsdale, NY), Sirotnak; Francis (Hampton Bays, NY)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY)
Filing Date:May 31, 2005
Application Number:11/568,254
Claims:1. A method for treatment of lymphoma comprising administering to a human patient diagnosed as having a lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin and a therapeutically effective amount of gemcitabine.

2. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.

3. The method of claim 2, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.

4. The method of claim 3, wherein the 10-propargyl-10-deazaaminopterin is administered weekly.

5. The method of claim 4, wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m.sup.2.

6. The method of claim 3, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg/m.sup.2 per dose.

7. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.

8. The method of claim 7, wherein the 10-propargyl-10-deazaaminopterin is administered in a dosage amount of 135 to 275 mg/m.sup.2.

9. The method of claim 1, wherein gemcitabine is administered after the 10-propargyl-10-deazaaminopterin.

10. The method of claim 1, wherein the lymphoma is non-Hodgkin's lymphoma.

11. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m.sup.2 per dose.

12. The method of claim 11, wherein the 10-propargyl-10-deazaaminopterin is administered weekly.

13. The method of claim 12, wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m.sup.2.

14. The method of claim 11, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg/m.sup.2 per dose.

15. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of 40 to 120 mg/m.sup.2 per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc